Primary outcome
Results for primary and secondary endpoints in each study are summarized
in table 3. There was no difference in mortality at follow-up between
patients who underwent MI and MS (IRR: 0.98 [95% CI: 0.25–3.82],
p = 0.98) and the groups were homogeneous (χ2 1.5,
I2 0%, p=0.91). Similarly there was no difference in
tumor recurrence (IRR: 1.13[0.26-4.88], p=0.87) with low
heterogeneity (p=0.9) (figure 2 A/B ). The overall mean follow-up
duration was 33.31 months (range 3.7 -56 months).